MRI and breast cancer: Role in detection, diagnosis, and staging

ONCOLOGY

Volumn 21, Issue 12, 2007, Pages 1521-1530

  Bleicher, Richard J ^a   Morrow, Monica ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; GENE MUTATION; HUMAN; LUNG CARCINOMA; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; ORGAN PRESERVATION; PAGET SKIN DISEASE; REVIEW; TREATMENT RESPONSE; TUMOR VOLUME; ULTRASOUND;

BREAST NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MASTECTOMY, SEGMENTAL; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY;

EID: 37149022051     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005.
2. Pisano ED, Gatsonis C, Hendrick E, et al: Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:1173-1183, 2005.
3. Kuhl CK, Schrading S, Leutner CC, et al: Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23:8469-8476, 2005.
4. Leach MO, Boggis CR, Dixon AK, et al: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 365:1769-1778, 2005.
5. Lehman CD, Blume JD, Weatherall P, et al: Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103:1898-1905, 2005.
6. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325, 2004.
7. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004.
8. Saslow D, Boetes C, Burke W, et al: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: Cancer J Clin 57:75-89, 2007.
9. Port ER, Park A, Borgen PI, et al: Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. Ann Surg Oncol 14:1051-1057, 2007.
10. Morrow M, Harris JR: Practice guideline for breast conservation therapy in the management of invasive breast cancer. J Am Coll Surg 205:362-376, 2007.
11. Morrow M, Schmidt R, Hassett C: Patient selection for breast conservation therapy with magnification mammography. Surgery 118:621-626, 1995.
12. Morrow M, Schmidt RA, Bucci C: Breast conservation for mammographically occult carcinoma. Ann Surg 227:502-506, 1998.
13. Yeatman TJ, Cantor AB, Smith TJ, et al: Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 222:549-561 (incl discussion), 1995.
14. Morrow M, Keeney K, Schottens D, et al: Selecting patients for breast-conserving therapy: The importance of lobular histology. Cancer 106:2563-2568, 2006.
15. Wapnir I, Anderson S, Mamounas E, et al: Survival after IBTR in NSABP node negative protocols B-13, B-14, B-19, B-20 and B-23 (abstract 517). J Clin Oncol 23(16S):8s, 2005.
16. Orel SG, Schnall MD, Powell CM, et al: Staging of suspected breast cancer: Effect of MR imaging and MR-guided biopsy. Radiology 196:115-122, 1995.
17. Boetes C, Mus RD, Holland R, et al: Breast tumors: Comparative accuracy of MR imaging relative to mammography and us for demonstrating extent. Radiology 197:743-747, 1995.
18. Mumtaz H, Hall-Craggs MA, Davidson T, et al: Staging of symptomatic primary breast cancer with MR imaging. AJR 169:417-424, 1997.
19. Fischer U, Kopka L, Grabbe E: Breast carcinoma: Effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 213:881-888, 1999.
20. Drew PJ, Chatterjee S, Turnbull LW, et al: Dynamic contrast enhanced magnetic resonance imaging of the breast is superior to triple assessment for the pre-operative detection of multifocal breast cancer. Ann Surg Oncol 6:599-603, 1999.
21. Bedrosian I, Mick R, Orel SG, et al: Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 98:468-473, 2003.
22. Liberman L, Morris EA, Dershaw DD, et al: MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR 180:901-910, 2003.
23. Bluemke DA, Gatsonis CA, Chen MH, et al: Magnetic resonance imaging of the breast prior to biopsy. JAMA 292:2735-2742, 2004.
24. Berg WA, Gutierrez L, NessAiver MS, et al: Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 233:830-849, 2004.
25. Deurloo EE, Peterse JL, Rutgers EJ, et al: Additional breast lesions in patients eligible for breast-conserving therapy by MRI: Impact on preoperative management and potential benefit of computerised analysis. Eur J Cancer 41:1393-1401, 2005.
26. Bilimoria KY, Cambic A, Hansen NM, et al: Evaluating the impact of preoperative breast magnetic resonance imaging on the surgical management of newly diagnosed breast cancers. Arch Surg 142:441-447, 2007.
27. Weinstein SP, Orel SG, Heller R, et al: MR imaging of the breast in patients with invasive lobular carcinoma. AJR 176:399-406, 2001.
28. Schelfout K, Van Goethem M, Kersschot E, et al: Preoperative breast MRI in patients with invasive lobular breast cancer. Eur Radiol 14:1209-1216, 2004.
29. Quan ML, Sclafani L, Heerdt AS, et al: Magnetic resonance imaging detects unsuspected disease in patients with invasive lobular cancer. Ann Surg Oncol 10:1048-1053, 2003.
30. Peiro G, Bornstein BA, Connolly JL, et al: The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 59:49-54, 2000.
31. Santiago RJ, Harris EE, Qin L, et al: Similar long-term results of breast-conservation treatment for stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast. Cancer 103:2447-2454, 2005.
32. Winchester DJ, Chang HR, Graves TA, et al: A comparative analysis of lobular and ductal carcinoma of the breast: Presentation, treatment, and outcomes. J Am Coll Surg 186:416-422, 1998.
33. Morrow M, Bucci C, Rademaker A: Medical contraindications are not a major factor in the underutilization of breast conserving therapy. J Am Coll Surg 186:269-274, 1998.
34. Qualheim RE, Gall EA: Breast carcinoma with multiple sites of origin. Cancer 10:460-468, 1957.
35. Rosen PP, Fracchia AA, Urban JA, et al: "Residual" mammary carcinoma following simulated partial mastectomy. Cancer 35:739-747, 1975.
36. Lagios MD: Multicentricity of breast carcinoma demonstrated by routine correlated serial subgross and radiographic examination. Cancer 40:1726-1734, 1977.
37. Egan RL: Multicentric breast carcinomas: Clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer 49:1123-1130, 1982.
38. Schwartz GF, Patchesfsky AS, Feig SA, et al: Multicentricity of non-palpable breast cancer. Cancer 45:2913-2916, 1980.
39. Vaidya JS, Vyas JJ, Chinoy RF, et al: Multicentricity of breast cancer: Whole-organ analysis and clinical implications. Br J Cancer 74:820-824, 1996.
40. Anastassiades O, Iakovou E, Stavridou N, et al: Multicentricity in breast cancer. A study of 366 cases. Am J Clin Pathol 99:238-243, 1993.
41. Holland R, Veling SH, Mravunac M, et al: Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 56:979-990, 1985.
42. Sardanelli F, Giuseppetti GM, Panizza P, et al: Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR 183:1149-1157, 2004.
43. Fischer U, Zachariae O, Baum F, et al: The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 14:1725-1731, 2004.
44. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996.
45. Fisher B, Dignam J, Mamounas EP, et al: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14:1982-1992, 1996.
46. Esserman L, Hylton N, Yassa L, et al: Utility of magnetic resonance imaging in the management of breast cancer: Evidence for improved preoperative staging. J Clin Oncol 17:110-119, 1999.
47. Wallace AM, Daniel BL, Jeffrey SS, et al: Rates of reexcision for breast cancer after magnetic resonance imaging-guided bracket wire localization. J Am Coll Surg 200:527-537, 2005.
48. Buchanan CL, Morris EA, Dorn PL, et al: Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 12:1045-1053, 2005.
49. Olson JA Jr, Morris EA, Van Zee KJ, et al: Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 7:411-415, 2000.
50. Orel SG, Weinstein SP, Schnall MD, et al: Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 212:543-549, 1999.
51. Henry-Tillman RS, Harms SE, Westbrook KC, et al: Role of breast magnetic resonance imaging in determining breast as a source of unknown metastatic lymphadenopathy. Am J Surg 178:496-500, 1999.
52. Morris EA, Schwartz LH, Dershaw DD, et al: MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 205:437-440, 1997.
53. McMahon K, Medoro L, Kennedy D: Breast magnetic resonance imaging: An essential role in malignant axillary lymphadenopathy of unknown origin. Australas Radiol 49:382-389, 2005.
54. Stomper PC, Waddell BE, Edge SB, et al: Breast MRI in the evaluation of patients with occult primary breast carcinoma. Breast J 5:230-234, 1999.
55. Tilanus-Linthorst MM, Obdeijn AI, Bontenbal M, et al: MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat 44:179-182, 1997.
56. Foroudi F, Tiver KW: Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys 47:143-147, 2000.
57. Varadarajan R, Edge SB, Yu J, et al: Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 71:456-459, 2007.
58. Kothari AS, Beechey-Newman N, Hamed H, et al: Paget disease of the nipple: A multifocal manifestation of higher-risk disease. Cancer 95:1-7, 2002.
59. Echevarria JJ, Lopez-Ruiz JA, Martin D, et al: Usefulness of MRI in detecting occult breast cancer associated with Paget's disease of the nipple-areolar complex. Br J Radiol 77:1036-1039, 2004.
60. Kaufmann M, von Minckwitz G, Smith R, et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 21:2600-2608, 2003.
61. Segara D, Krop IE, Garber JE, et al: Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol July 19, 2007 (epub ahead of print).
62. Gilles R, Guinebretiere JM, Toussaint C, et al: Locally advanced breast cancer: Contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 191:633-638, 1994.
63. Rosen EL, Blackwell KL, Baker JA, et al: Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR 181:1275-1282, 2003.
64. Julius T, Kemp SE, Kneeshaw PJ, et al: MRI and conservative treatment of locally advanced breast cancer. Eur J Surg Oncol 31:1129-1134, 2005.
65. Schott AF, Roubidoux MA, Helvie MA, et al: Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92:231-238, 2005.
66. Garimella V, Qutob O, Fox JN, et al: Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol 33:157-161, 2007.
67. Belli P, Costantini M, Malaspina C, et al: MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 61:946-953, 2006.
68. Denis F, Desbiez-Bourcier AV, Chapiron C, et al: Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 30:1069-1076, 2004.
69. Voogd AC, van Tienhoven G, Peterse HL, et al: Local recurrence after breast conservation therapy for early stage breast carcinoma. Detection, treatment, and outcome in 266 patients. Cancer 85:437-446, 1999.
70. van Tienhoven G, Voogd AC, Peterse JL, et al: Prognosis after treatment for locoregional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82tm). Eur J Cancer 35:32-38, 1999.
71. Veronesi U, Marubini E, Del Vecchio M, et al: Local recurrences and distant metastases after conservative breast cancer treatments: Partly independent events. J Natl Cancer Inst 87:19-27, 1995.
72. Lehman CD, Gatsonis C, Kuhl CK, et al: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356:1295-1303, 2007.
73. Gao X, Fisher SG, Emami B: Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study. Int J Radiat Oncol Biol Phys 56:1038-1045, 2003.
74. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.